- Conditions
- Migraine
- Interventions
- Placebo, Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 6,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insomnia
- Interventions
- PD 0200390, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- HIV Infections
- Interventions
- Atazanavir+ritonavir, Lopinavir+ritonavir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 52
- States / cities
- Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
- Conditions
- Crohn's Disease
- Interventions
- IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 87
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Survodutide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
- Conditions
- Major Depressive Disorder
- Interventions
- Cariprazine, Placebo, Antidepressant Therapy (ADT)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 83
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
- Conditions
- Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Pembrolizumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 220
- States / cities
- Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
- Conditions
- Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Interventions
- Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 914
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
- Conditions
- Pain
- Interventions
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Epilepsy
- Interventions
- Staccato Alprazolam, Placebos
- Drug
- Lead sponsor
- Engage Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 72
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium
- Interventions
- Nighttime noise & light reduction, Clustering patient-care interactions, Non-pharmacologic sleep aids, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep
- Behavioral · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 4 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- No intervention
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
- Conditions
- Fibromyalgia
- Interventions
- Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Anaheim, California • Fair Oaks, California + 26 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- COMPASS Pathways
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- SX-682, Decitabine
- Drug
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Miami, Florida • Orlando, Florida + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- NMRA-335140, Placebo
- Drug
- Lead sponsor
- Neumora Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 57
- States / cities
- Encino, California • Garden Grove, California • Los Alamitos, California + 42 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
- Conditions
- Healthy
- Interventions
- ABT-143, ABT-335, rosuvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Cachexia
- Interventions
- AV-380
- Biological
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Lakewood, California • Newport Beach, California + 9 more